May 15, 2021

New fund to invest in Geroscience

Edge Capital has started a new fund to invest in biomedical technology focused on GeroScience.

Singapore, 15 May 2021 – Edge Capital Asset Management Pte. Ltd. (“Edge Capital”) has started its second fund - the Regenosis Gero-Science Fund SP (the “Fund”) to provide high net worth and institutional investors an opportunity to have exposure to the growing market of Geoscientific technology given the global ageing population.  

Scientific advances over the last decade has led to the development of new therapies to combat or even reverse the symptoms of ageing, such as reducing frailty and other ageing related conditions. The Fund has established a first panel of globally prominent scientists and leading figures in both the medical and biomedical research fields of GeroScience.

The panel has already lined up a proprietary pipeline of early to late stage companies to be invested in so as to create a balanced portfolio with the potential of foreseeable near to mid-term monetization events

The Fund's panel of scientists, physicians and key opinion leaders include Prof. Brian Kennedy, Director of the National University Health System Centre for Healthy Longevity and Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of Singapore, Prof. Matt Kaeberlein, Professor at the Department of Laboratory Medicine and Pathology and Director of the Healthy Aging and Longevity Research, University of Washington, and Prof. Zeng Xianmin, Visiting Professor at the National University of Singapore and Founder-cum-CEO of RxCell Inc. from specialties such as genome sciences and molecular biology.

Senior doctors that also form the Fund's panel include Dr. Ang Peng Tiam, Senior Consultant, Medical Oncologist, Parkway Cancer Centre and CEO of TalkMed Group, Dr. Teo Cheng Peng, Senior Consultant, Haematologist, Parkway Cancer Centre, Dr. Leong See Odd, Senior Consultant, Nephrologist, Gleneagles Hospital and Dr. Khoo Kei Siong, Senior Consultant, Medical Oncologist, Parkway Cancer Centre.

For more information and to invest, refer to

About Edge Capital Asset Management Pte. Ltd.

Edge Capital Asset Management (“Edge Capital”) is a fund management company regulated by the Monetary Authority of Singapore. Edge Capital is the investment manager to Edge Capital Fund SPC, a Cayman segregated portfolio company with various fund strategies. Edge Capital aims to be a fore runner in fund management both in Singapore and the region. Its portfolios are focused to provide exposure into niche areas where investors will benefit from high return multiples. All assets under management are actively managed for risk and towards delivering strong performance for investors.

For enquiries please contact - Email:, Tel: +(65) 3150 2316

‍Important Notes and Disclaimer

Additional information including private placement memorandum, associated appendix and subscription documents are available upon request. The information including projections in this material has been obtained and derived from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, Edge Capital Asset Management Pte. Ltd. or its affiliates and/or subsidiaries (collectively “Edge Capital”) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to Edge Capital. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. Any data discrepancies in this material could be the result of different calculations and/or adjustments. Edge Capital accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither Edge Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent Edge Capital current opinions or judgment as of the date of the material only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or also be affected by changes in exchange rates. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. This material does not constitute an offer to buy or solicitation of an offer to invest, or to procure an investment in or sell any funds or investment vehicles in any jurisdiction in which an offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation and is for information purposes only.  Subscriptions to any fund will only be received from professional and accredited investors and investments are accepted only on the basis of the current private placement memorandum and relevant appendix of the fund. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipients of this material must make their own independent decisions regarding an investment into the fund and any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. Funds managed by Edge Capital are currently open for subscription by non-United States of America persons only, unless otherwise stated.